发明名称 |
B AND T LYMPHOCYTE ATTENUATOR MARKER FOR USE IN ADOPTIVE T-CELL THERAPY |
摘要 |
BTLA-positive ("BTLA+") lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes. |
申请公布号 |
WO2012044933(A3) |
申请公布日期 |
2012.06.14 |
申请号 |
WO2011US54222 |
申请日期 |
2011.09.30 |
申请人 |
1/4BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;RADVANYI, LASZLO;HWU, PATRICK;BERNATCHEZ, CHANTALE |
发明人 |
RADVANYI, LASZLO;HWU, PATRICK;BERNATCHEZ, CHANTALE |
分类号 |
C12Q1/02;A61K35/26;A61P35/00;C12N5/0783;G01N33/50 |
主分类号 |
C12Q1/02 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|